Comparisons
Semaglutide vs retatrutide: what we know so far
How semaglutide and retatrutide compare on mechanism, evidence, availability, and what is actually known about them in 2025.
7 min read · Updated 2026-05-27
Peptide GPS publishes educational information, not medical advice. We don't sell, prescribe, or recommend specific medications, dosages, or providers. Always discuss any therapy with a licensed clinician.
Key takeaways
- Different mechanisms (single vs triple agonist) and very different evidence bases.
- Semaglutide is approved and prescribed; retatrutide is investigational.
- Cross-trial comparisons are not the same as head-to-head evidence.
Mechanism
activates one : .
activates three: GLP-1, , and .
Hitting more receptors is not automatically better, but it does explain why the two drugs produce different magnitudes of effect in trials.
For drug-specific background, see what is semaglutide? and what is retatrutide?.
Evidence base
Semaglutide has years of large data, post-marketing surveillance, and cardiovascular outcome data in real-world populations.
Retatrutide has data and ongoing Phase 3 trials. Long-term safety, durability after stopping, and rare adverse events are still being characterized.
For more on how retatrutide has been dosed in the trial program, see how retatrutide dosing appears in clinical trials.
Availability
Semaglutide is and available by prescription (Ozempic, Wegovy, Rybelsus), and at times has been during shortage periods.
Retatrutide is not approved and is not available by prescription. Anything sold online under that name is unregulated.
Why this comparison is harder than it looks
Comparing average weight loss percentages across trials with different designs, populations, and durations is a common source of misleading headlines.
Side effect profiles also differ — the addition of glucagon agonism in retatrutide may have effects that single-receptor GLP-1 drugs do not.
Until head-to-head trials report, statements about which is ''more effective'' or ''safer'' for a given person are claims, not conclusions.
Get the weekly brief
One plain-English email per week on GLP-1s, peptides, and the regulation around them.